EU Horizon funding · France · NACE 21
Horizon Europe funding for pharmaceutical companies in France
NACE 21 · Manufacture of basic pharmaceutical products and pharmaceutical preparations
12 pharmaceutical companies in France received €9.7M in EU research and innovation funding across 16 Horizon Europe and Horizon 2020 projects starting between 2015 and 2025; 69% of the money went to SMEs.
- EU contribution
- €9.7M
- 2015–2025 project starts
- Funded companies
- 12
- 6 of them SMEs
- Projects
- 16
- Horizon Europe and Horizon 2020
- Share to SMEs
- 69%
- €6.7M to SMEs
Industry is known only for companies in France that we matched to the national business register; funded companies we could not match are counted on the France country page but not here.
In numbers
Pharmaceutical companies in France rank 32nd of 44 industry divisions in France by total EU funding received.
Of the total, Horizon 2020 (2014–2020) accounts for €6.1M across 6 projects and Horizon Europe (2021–2027) for €3.6M across 10 projects.
The strongest start year was 2015, when projects worth €5.1M to these companies began.
The largest funding route was the SME Instrument Phase 2 with €5M (52% of the total, 1 project).
Firalis Molecular Precision (Huningue) is the largest recipient with €5M over 1 project; the 10 largest recipients together received 99% of the total.
The average funded company received €805k; 50% of the companies are SMEs.
By programme
Horizon 2020 2014–2020
€6.1M
6 projects · 63% of the total
Horizon Europe 2021–2027
€3.6M
10 projects · 37% of the total
Funding by start year
EU contribution to these companies, by the year their project started.
| Year | EU contribution |
|---|---|
| 2015 |
€5.1M
|
| 2016 |
€50k
|
| 2017 |
€151k
|
| 2019 |
€769k
|
| 2022 |
€771k
|
| 2023 |
€1.8M
|
| 2024 |
€404k
|
| 2025 |
€600k
|
2014–2020 starts (mostly Horizon 2020) 2021 onwards (Horizon Europe)
Largest recipients
Companies with the highest EU contribution, Horizon Europe and Horizon 2020 combined.
| # | Company | Programmes | Projects | EU contribution |
|---|---|---|---|---|
| 1 | Firalis Molecular Precision SME Huningue | Horizon 2020 | 1 | €5M |
| 2 | Adhexpharma Paris | Horizon 2020, Horizon Europe | 2 | €1.2M |
| 3 | Societe de Systemes Biologiques SME Apprieu | Horizon Europe | 2 | €848k |
| 4 | Guerbet Villepinte | Horizon Europe | 1 | €600k |
| 5 | Biopredic International SME Saint-Gregoire | Horizon 2020, Horizon Europe | 2 | €567k |
| 6 | Boehringer Ingelheim Animal Health France Lyon | Horizon Europe | 1 | €422k |
| 7 | Laboratoires Kol Clermont-Ferrand | Horizon Europe | 1 | €414k |
| 8 | Ceva Sante Animale Libourne | Horizon 2020, Horizon Europe | 2 | €176k |
| 9 | Covalab SME Bron | Horizon Europe | 1 | €175k |
| 10 | Laboratoires Urgo Chenove | Horizon 2020 | 1 | €96k |
Funding schemes
How the money reached these companies.
-
SME Instrument Phase 2 €5M1 project SME-2 52%
-
Research and Innovation Action (RIA) €2.4M7 projects HORIZON-RIA · RIA 25%
-
EIC Pathfinder & Transition €1M2 projects HORIZON-EIC 10%
-
Innovation Action (IA) €973k3 projects HORIZON-IA · IA 10%
-
Marie Skłodowska-Curie Actions €175k1 project HORIZON-TMA-MSCA-SE 2%
-
Coordination and Support Action (CSA) €75k1 project HORIZON-CSA 1%
Notable recent projects
Recent projects with the largest EU contribution to these companies. Links open the project on CORDIS.
-
ScanNanoTreat
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
Started 2025 Horizon Europe EIC Pathfinder & Transition Total EU contribution €2.5M to these companies €600k
-
ABCardionostics
Human Antibody-enabled Cardiovascular Personalized Theranosis
Started 2024 Horizon Europe EIC Pathfinder & Transition Total EU contribution €3.6M to these companies €404k
-
RABIOPRED
RABIOPRED - Clinical validation of BIOmarker assay to PREDict treatment response in Rheumatoid Arthritis (RA) patients
Started 2015 Horizon 2020 SME Instrument Phase 2 Total EU contribution €5M to these companies €5M
-
BUCCAL-PEP
Development of a multifunctional biomaterial patch for buccal delivery of peptide-analogue treatments
Started 2023 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €4M to these companies €713k
-
DERMAREP
Clinical validation and production upscaling of a novel product for healing of Pressure Ulcers, Leg Ulcers and Diabetic Foot Ulcers.
Started 2019 Horizon 2020 Innovation Action (IA) Total EU contribution €3M to these companies €525k
Other funded industries in France
| Industry (NACE) | Companies | Projects | To SMEs | EU contribution |
|---|---|---|---|---|
| 30 Transport Equipment Manufacturing | 50 | 429 | 2% |
€811M
|
| 72 Research & Development | 354 | 958 | 70% |
€596M
|
| 26 Electronics Manufacturing | 174 | 597 | 21% |
€546M
|
| 71 Architecture & Engineering | 470 | 973 | 64% |
€524M
|
| 62 Software & IT Services | 295 | 758 | 56% |
€423M
|
| 70 Management Consulting | 176 | 942 | 40% |
€331M
|
| 20 Chemicals Manufacturing | 70 | 192 | 45% |
€146M
|
| 35 Energy Supply | 23 | 252 | 4% |
€124M
|
| 27 Electrical Equipment Manufacturing | 48 | 127 | 6% |
€113M
|
| 74 Other Professional & Technical Services | 136 | 295 | 88% |
€102M
|
Pharmaceutical in other countries
Get company lists in Claude
Ask Claude for companies by industry, size and region, straight from official European business registers, and export the list as CSV.
Source and method
Source: CORDIS – © European Union, 1994–2026, CC BY 4.0. Data modified: aggregated by EU Company Leads. Project and participant data from CORDIS (Horizon Europe and Horizon 2020 project datasets), licensed under CC BY 4.0.
We count organisations that CORDIS lists as private for-profit companies (activity type PRC) with an EU contribution above zero. Amounts are the EU contribution to those companies, not total project budgets; years are project start years. Industries use NACE Rev. 2.1 from the national business registers of France, Finland, Belgium, Estonia, Sweden and Czech Republic and are only known for companies matched to those registers. Figures computed Nov 17, 2026.